Format

Send to

Choose Destination
J Blood Med. 2014 Apr 28;5:43-8. doi: 10.2147/JBM.S57887. eCollection 2014.

Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience.

Author information

1
Hospital Universitario 12 de Octubre, Ctra Andalucía, Madrid, Spain.
2
1Hospital Universitario 12 de Octubre, Ctra Andalucía, Madrid, Spain.
3
Zentralklinikum Suhl, Suhl, Germany.
4
Sandoz International GmbH, Holzkirchen, Germany.
5
Sandoz Farmaceutica SA, Madrid, Spain.
6
Frauenarztpraxis, Hildburghausen, Germany.

Erratum in

  • J Blood Med. 2014;5:129. Cortijo Casacajares, Susana [added]; Pernaut, Cristina [added]; Ruiz Ares, Gustavo Javier [added]; Otero Blas, Irene [added]; Cortes Funes, Hernan [added].

Abstract

BACKGROUND:

The purpose of this paper is to report real-world data on the relative effectiveness of a biosimilar erythropoiesis-stimulating agent (ESA; Binocrit(®)), and other available ESAs for the treatment of chemotherapy-induced anemia.

METHODS:

Data were collected retrospectively from single centers in Spain (n=284) and Germany (n=145). Hemoglobin outcomes, transfusion requirements, and serious drug-related adverse events were assessed for each ESA.

RESULTS:

Hemoglobin outcomes and transfusion requirements were generally similar in the different ESA treatment groups assessed. No serious drug-related adverse events were recorded in any of the treatment groups.

CONCLUSION:

These data confirm the real-world effectiveness and safety of a biosimilar ESA (Binocrit(®)) for the treatment of cancer patients with chemotherapy-induced anemia.

KEYWORDS:

biosimilar; chemotherapy-induced anemia; erythropoiesis-stimulating agents

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center